Who owns Buscolysin?
Buscolysin is owned by Sopharma (Bulgaria, BSE Sofia: SFA).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Key facts
- Current owner
- Sopharma AD reported
- Owned since
- Not recorded
- Previous owner
- None recorded
- Owner HQ
- 🇧🇬 Bulgaria, Sofia
- Origin
- 🇧🇬 Bulgaria
- Category
- Consumer health › Over-the-counter medicine › Digestive health
- Parent ticker
- BSE Sofia: SFA WSE: SPH
- Last verified
- · 1 sources
About Buscolysin
Buscolysin is Sopharma's butylscopolamine tablet, registered in Poland during the first half of 2026 both as a 10 mg film-coated tablet and, as Buscolysin Forte, at 20 mg. A 20 mg tablet is also among the products the company has in pharmaceutical development. Sopharma's half-year report lists Buscolysin among the products with the largest share of its sales in Bulgaria.
Ownership timeline of Buscolysin
Where Buscolysin sits in Sopharma
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Sopharma ownership tree →
Other brands owned by Sopharma in consumer health
Latest news about Buscolysin
No tagged news items yet. Deals, regulatory actions and recalls are added from SEC filings, regulators and trade press; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
Frequently asked questions
Who is the parent company of Buscolysin?
The parent company of Buscolysin is Sopharma, a publicly listed company headquartered in Bulgaria.
Is Buscolysin Bulgarian?
Yes. Buscolysin originated in Bulgaria and its owner, Sopharma, is also headquartered in Bulgaria.
Is Buscolysin still owned by Sopharma?
Yes. As of 20 September 2026, Buscolysin is still owned by Sopharma. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Sopharma Group consolidated management report for the first half of 2026 — Sopharma AD, Stock exchange filing, published 30 June 2026; retrieved 20 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.